Discover and read the best of Twitter Threads about #Interferon

Most recents (10)

Pr que cela soit clair #Solidarity auquel #DisCoVeRy fournit les données de mortalité des patients a tiré au sort 1853 patients. La moitié ont eu l'hydroxychloroquine l'autre moitié rien.

Mortalité #HCQ : 11% (104/947)
Mortalité sans #HCQ : 9% (84/906)

medrxiv.org/content/10.110…
A tiré au sort 5451 patients entre remdesivir et pas de remdesivir

Mortalité #Remdesivir : 11% (301/2743)
Mortalité sans #Remdesivir : 11% (303/2708)
A tiré au sort 2771 patients entre lopinavir/ritonavir et pas de lopinavir/ritonavir

Mortalité #Lopinavir/ritonavir : 11% (301/2743)
Mortalité sans #Lopinavir/ritonavir : 11% (303/2708)
Read 4 tweets
🤧🤒 Erkältungssaison! Warum manche Viren sich nur zu bestimmten Jahreszeiten schlagartig verbreiten und ob das auch für #SARSCoV2 / #COVID19 eine Rolle spielt!

Hier ein kleiner Thread anlässlich des aktuellen Artikels von @Weber_Nina @derspiegel

spiegel.de/wissenschaft/m…

1/
„Saisonalität“ bei #Virusinfektionen ist extrem komplex. Eine hervorragende Übersicht bieten auch @VirusesImmunity (annualreviews.org/doi/10.1146/an…, hieraus einige Abbildungen im Thread!) oder auch @riffreporter ausführlich und auf deutsch (riffreporter.de/taktvoll/epide…).
2/
Hauptfaktoren für Saisonalität sind 1) Wetter, 2) Raumklima und 3) unser Sozialverhalten. Für jedes Virus gibt es eine optimale Kombination aus diesen Umgebungsfaktoren, unter denen es sich dann am effizientesten verbreitet. #Influenza Nov-Apr, „normale“ #Coronaviren Dez-Apr, 3/
Read 27 tweets
Time to share some thoughts and questions following the .@medrxivpreprint first release of results from the #SolidarityTrial that compared local standard care to #remdesivir, #HydroxyChloroquine #lopinavir_ritonavir and #interferon for treatment of patients with #COVID19
I have read the #solidarityTrial preprint: medrxiv.org/content/10.110…

Its supplementary material:medrxiv.org/content/10.110…

its posted protocol: who.int/publications/m…

The CRF: who.int/publications/i…

The final report from #ACTT1 for contrast: nejm.org/doi/full/10.10…
Everyone has focused on the results, which is understandable, yet understanding the specifics in #SolidarityTrial design compared to the #ACTT1 design, may bring light into the differences reported between trials and may give a way to do better in #COVID19 #therapeutics
Read 26 tweets
The preprints of the #SOLIDARITY trial are out on MedRxiv. While many may lament that all four drugs tested did not show benefit, this is a remarkable trial for many reasons. Thread
First, this was another #MultiArmMultiStage #MAMS study design; @MRCCTU made this highly efficient trial design globally acclaimed with #STAMPEDE. The more recent #RECOVERY trial was another example of this.
@MaxParmarMRCUCL @Prof_Nick_James @PeterHorby @MartinLandray
What the #MAMS design does is enable testing multiple drugs simultaneously, flexibility to drop unpromising ones & add new promising ones even midway during the trial. This was crucial in the #COVID__19 pandemic where the situation has been constantly evolving
Read 16 tweets
🔥Les résultat de #Solidarity @WHO, essai mère de #DisCoVeRy sont là

Confirme déception des antiviraux "repositionnés"

Nbre de patients impressionnant : 2750 Remdesivir, 954 Hydroxychloroquine, 1411 Lopinavir, 651 Interferon+Lopinavir, 1412 Interferon, and 4088 no study drug
405 hôpitaux, 30 pays, c'est ENORME !
On juge de la mortalité, un critère fort

#Hydroxychloroquine : va dans le sens d'augmentation de la mortalité mais NON SIGNIFICATIF donc on ne peut rien dire
#Remdesivir : AUCUNE DIFFERENCE DE MORTALITE, comme on le dit depuis des mois en analysant les différents essais
Read 10 tweets
🔥Voilà un thread afin de ne pas avoir à répéter tout le temps la même chose sur la recherche médicale thérapeutique pendant #COVID19 #SARS_CoV_2 #pandemic

👇👇
1/ Les infectiologues cliniciens n'attendaient pas de ttt antiviral permettant une amélioration "spectaculaire" pr une maladie aiguë virale sévère (cf dengue, zika, chik, grippe), il était donc nécessaire d’évaluer rigoureusement et d’espérer un ttt un peu efficace et non toxique
2/ Il existe de nombreux candidats repositionnés qui ont été utilisés et testés et ce dès le début de la pandémie : #lopinavir/#ritonavir, #remdesivir, #hydroxychloroquine, #interferon ß pour n’en citer que quelques-uns
Read 35 tweets
A #practical topic for today. #Pregnancy changes things - but more so for our #neurology patients - or not? #pearls from the #EAN2020 #MedEd #MedTwitter #MedStudentTwitter #neurologyresident @EANeurology @WNGtweets
Let’s first address #multiplesclerosis. Patients get better in third trimester and 30% relapse #postpartum. Immune responses shifts to anti-inflammatory in 3rd trimester to accommodate fetus - #etcomehome - but rebounds after birth. #MedEd #doubledoc #AcademicTwitter
Continue #firstlineinjectables #glatiramer and #interferon - these don’t cause #teratogenicity. In flares, consider IVIG and PLEX. How about #steroids? Usually fine except in 1st trimester when they can cause birth defects #MedEd #MedStudentTwitter #MedTwitter
Read 6 tweets
1/
Should we use #Lopinavir-ritonavir (LPV/r) + #Ribavirin (RBV) +/- #Interferon beta-1b (IFN) to treat #SARSCoV2 #COVID19? Let’s take a look at the data.

Here’s: #HowIReadThisPaper on @TheLancet trial of triple therapy for COVID19

Hung et al: thelancet.com/journals/lance…
2/
First, let’s assess our baseline beliefs about triple therapy:

Before reading this study, when considering triple therapy as a treatment for patients with COVID19, I think the most important component is likely to be:
3/
Background: A 2003 case series suggested ↓mortality (vs historical controls) in SARS patients treated with LPV/r + RBV :

ncbi.nlm.nih.gov/pmc/articles/P…

In 2015, LPV/r and IFN led to ↓viral load and improved clinical outcomes in animal models of MERS:

pubmed.ncbi.nlm.nih.gov/26198719/
Read 30 tweets
1/8 Pharmacien Hospitalier clinicien en réanimation et chercheur à Amiens, Je vois nos capacités de soins de réanimation en extrême tension et une prise en charge du #COVID-19 sans consensus.
2/8 Afin de trouver la meilleure thérapeutique je souhaite apporter mon analyse. L’#hydroxychloroquine est cardiotoxique pour au moins 2-3 mois, ce qui risqué chez les personnes fragiles, justement sujettes aux formes sévères du COVID.
3/8 L’#azithromicine (sécréteur d’Interferon I) suffirait-elle ? Les chinois ont montré que l’#hydroxychloroquine n’apportait rien à de l'interféron α2b inhalé + antiviral subject.med.wanfangdata.com.cn/UpLoad/Files/2…
Read 8 tweets
Starting a series on clinical Pearls I am gathering in #COVID19 patients based on experiences of many experts

Will add as we go along

Feel free to add your own observations/experiences

#covidclinicalpearls /1
Anosmia is likely the most specific #COVID19 related symptom
30% of patients have anosmia as their 1st symptom
#covidclinicalpearls /2
Around 90% of patients have fever.
50% maybe afebrile at the time of presentation
Fever tends to be very resistant to routine measures in hospitalized patients
There is no consensus that NSAIDs are to be avoided in #COVID2019 patients

#covidclinicalpearls /3
Read 66 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!